drugset
drugset / Trial / NCT04000009

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009 ↗

Phase 3 Terminated 235 enrolled ACADIA Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Timeline

Start
2019-06-06
Primary completion
2021-02-22
Completion
2021-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 34 mg Oral

Indications

No indication recorded.